Published in Cancer Weekly, April 26th, 2005
This new standard is formally recognized by the European Commission as a key quality assurance requirement for CE Mark approval of medical devices, such as the rapid HIV test, for the European Union (EU).
"Our rapid testing products are known leaders in global healthcare markets for three main attributes; our highest quality standards, excellent performance, and as one of the only true rapid tests available - with results in just 3 minutes," said Hermes Chan, president and chief operating officer of MedMira.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.